Aurobindo Pharma opens TheraNym biologics CMO in 2026

Aurobindo’s entry into biologics CDMO

Aurobindo Pharma has formally entered the biologics contract manufacturing segment with the inauguration of TheraNym, a dedicated facility in Telangana built to manufacture biologic medicines for global markets. The company’s move marks a clear push beyond its traditional generics business into biologics and the contract development and manufacturing (CDMO) space. US pharma major MSD, known as Merck & Co. in the US and Canada, has signed on as the anchor customer for the new platform. The announcement puts focus on Aurobindo’s plan to build a scaled manufacturing base in a segment that typically demands high capital investment, strict compliance, and long qualification cycles. The facility has been positioned to support global biologics supply chains, with manufacturing intended for both domestic and export markets. Exports, including to the United States, are planned subject to regulatory approvals and customer requirements. For investors tracking Indian pharma, the development is notable because contract manufacturing relationships in biologics can be multi-year and capacity-linked.

Location and inauguration details

The TheraNym facility is located at Borapatla in Telangana, described as being in Sangareddy district near Hyderabad, and about 45 minutes from Hyderabad’s Financial District. The inauguration took place in the presence of Telangana ministers Shri D. Sridhar Babu and Shri Damodar Raja Narasimha, according to the information provided. Local reporting also placed the facility at Borpatla village in Hatnoora mandal of Sangareddy district. In a separate market disclosure context, the location was specified as Borapatla (V), Hathnoora Mandal, Medak District, Telangana. Taken together, the consistent detail is that the site is at Borapatla in Telangana, in the Hyderabad region, and is being developed as a large-scale biologics manufacturing base. The project has also been presented as a step toward strengthening Hyderabad’s broader life sciences manufacturing ecosystem.

Investment size and the project’s scale

Reports around the launch described TheraNym as a Rs 1,200-crore facility in Telangana. Separately, Aurobindo disclosed that it would spend Rs 1,000 crore to set up a biologics manufacturing facility at Borapatla in Telangana, in the context of its manufacturing arrangement with MSD. The inputs provided do not explicitly reconcile whether these figures refer to the same scope of work or different phases of investment, so both have been cited as reported. What is clear is that the spending is aimed at establishing commercial-scale infrastructure for biologics, including large-scale bioreactors and fill-finish capability. The company has described the facility as being built to meet international regulatory expectations, which is a central requirement for exporting biologics to regulated markets. Aurobindo also said the site is designed to serve both domestic and export markets, subject to approvals and customer requirements.

What TheraNym will manufacture

Aurobindo has stated that the TheraNym facility will manufacture biologic medicines for global markets. The plant has been described as designed to manufacture advanced therapeutics for cancer and other life-threatening diseases, with exports planned to multiple markets including the United States, subject to approvals. The company has framed the site as part of a broader effort to support global biologics supply chains. Because biologics manufacturing typically includes upstream cell culture, downstream purification, and sterile fill-finish steps, the facility’s stated configuration signals end-to-end capability. The design intent, as described, is not limited to India-focused supply, and it explicitly includes export supply potential.

Capacity and technology: bioreactors and fill-finish

Aurobindo said the TheraNym facility is equipped with 15 KL bioreactors, along with downstream processing suites. It also includes aseptic fill-finish capabilities and quality control laboratories, based on the details provided. In addition to the inaugurated setup, Aurobindo has described a vial filling isolator line designed to manufacture commercial drug products. The stated throughput for this vial filling isolator line is 25-30 million vials annually. These details matter for customers because biologics capacity is often qualified product-by-product, and fill-finish constraints can be as critical as drug substance capacity in meeting commercial demand.

MSD as anchor customer: what the agreement covers

MSD has joined as the anchor customer for the new facility. Aurobindo’s wholly-owned subsidiary, TheraNym Biologics, signed a Master Service Agreement (MSA) with Merck Sharp & Dohme Singapore Trading (MSD) for contract manufacturing of biological products for both domestic and international markets. Under the arrangement described, TheraNym will manufacture biologics on behalf of MSD and the scope includes building manufacturing infrastructure, producing products, and supplying them to MSD. The MSA was described as effective May 31, 2024. Aurobindo also indicated the contract manufacturing arrangement is expected to kick off by FY27.

Unit 2 expansion: 60,000-litre mammalian capacity

In a further expansion of the MSD relationship, TheraNym Biologics executed an additional product schedule under the existing CMO agreement. Under this newly signed product schedule, TheraNym will set up a greenfield project to establish a large-scale mammalian drug substance manufacturing facility referred to as “Unit 2.” The facility is planned with a total bioreactor capacity of 60 KL, described as an aggregate capacity of 60,000 litres, along with advanced downstream purification infrastructure for drug substance production. The investment for Unit 2 was stated at approximately USD 150-175 million, based on the disclosures cited. Under the arrangement, TheraNym will build the facility, manufacture the drug substances, and supply them to MSD.

Jobs and regional footprint

The TheraNym facility is expected to create more than 1,500 jobs. That employment impact is relevant for Telangana’s industrial policy focus, given the state’s established pharmaceutical and life sciences presence around Hyderabad. For Aurobindo, the local hiring and operations scale also indicate a long-term commitment to biologics manufacturing rather than a small pilot setup. The combination of upstream bioreactor capacity, downstream suites, aseptic fill-finish, and QC labs typically requires specialised technical roles across manufacturing, quality, engineering, and compliance.

Key facts at a glance

Timeline and market reaction

Aurobindo incorporated TheraNym in September 2022 as a wholly owned subsidiary to house its biologics contract manufacturing operations. The MSA with MSD was described as effective May 31, 2024, and the arrangement is expected to begin from FY27. The additional product schedule expands the existing CMO agreement and triggers the Unit 2 greenfield investment plan. On June 3, Aurobindo Pharma shares rose close to 4% after the market focused on the MSD manufacturing agreement and the broader biologics manufacturing plans.

Why this matters for Aurobindo and Indian pharma

Aurobindo’s move signals a strategic broadening from a generics-led base into biologics manufacturing services, where customer qualification and regulatory readiness are central. The presence of a global anchor customer such as MSD is material because biologics contracts often come with defined technical transfer requirements, validation timelines, and ongoing supply commitments. The combination of an operating site with 15 KL bioreactors and a proposed Unit 2 with 60,000 litres of mammalian capacity shows intent to scale drug substance manufacturing, not only final drug product operations. The reported inclusion of aseptic fill-finish and quality control laboratories also suggests the company is building capabilities that can support end-to-end supply, subject to approvals and customer requirements. The expected FY27 start for manufacturing under the MSD arrangement highlights that capacity build-out and compliance work will likely be a key execution focus over the next phases.

Conclusion

TheraNym’s inauguration near Hyderabad marks Aurobindo Pharma’s formal entry into biologics contract manufacturing, backed by a large investment footprint, bioreactor capacity, and a named anchor customer in MSD. The company has also outlined a Unit 2 expansion plan with 60,000 litres of mammalian bioreactor capacity and an investment of USD 150-175 million under an additional product schedule. Near-term milestones to watch, as stated, include execution progress toward the planned FY27 kickoff, and the regulatory approvals required for serving export markets including the United States.